CD BioGlyco offers a specialized sterile erythromycin gluceptate analysis service as part of our comprehensive Pharmaceutical Analysis Service, which is an integral component of our Pharmaceutical and Biological Analysis Service. This service is designed to provide accurate and reliable analysis for sterile erythromycin gluceptate, ensuring its quality and adherence to specific requirements.
Erythromycin gluceptate, a macrolide antibiotic derived from the actinomycete Streptomyces erythreus, demonstrates a broad spectrum of antimicrobial activity. By binding to bacterial 50S ribosomal subunits, it impedes RNA-dependent protein synthesis through the obstruction of transpeptidation and/or translocation reactions, without impacting nucleic acid synthesis. Beyond its antibiotic properties, erythromycin gluceptate showcases antitumor and neuroprotective effects, contributing to diverse areas of research.
Fig.1 The structure of erythromycin gluceptate. (CD BioGlyco)
Our sterile erythromycin gluceptate analysis service is capable of testing various formulations shown below. We employ mature experimental protocols to ensure precise and reliable analysis of these formulations. Our robust capabilities and well-established methodologies contribute to the accuracy and quality of our analytical services.
Fig.2 The preparations of erythromycin gluceptate can be analyzed. (CD BioGlyco)
Our comprehensive testing includes rigorous assessments such as sterility testing, pH testing, dissolution testing, and more. These analyses are crucial for confirming the purity, potency, and overall quality of sterile erythromycin gluceptate and related formulations.
Table 1. The test items included in the erythromycin gluceptate analysis service. (CD BioGlyco)
Sterile erythromycin gluceptate |
|
Erythromycin lactobionate for injection |
|
Sterile erythromycin lactobionate |
|
Erythromycin stearate |
|
Erythromycin stearate tablets |
|
Title: Erythromycin formulations—a journey to advanced drug delivery
Technology: Liposomes, Solid–lipid nanoparticles, Mesoporous oxides, Metallic-based nanoparticles
Journal: Pharmaceutics
IF: 5.4
Published: 2022
Results: Erythromycin, a broad-spectrum macrolide, has been pivotal in treating various bacterial infections since its discovery in 1952. However, challenges like low solubility and instability prompted diverse erythromycin formulations, including nanoparticles. This review comprehensively assesses efforts to encapsulate erythromycin in formulations, detailing their chemical compositions, sizes, morphologies, and physico-chemical properties. Despite the promising outcomes, the work emphasizes the existing limitations, particularly in erythromycin quantification, underscoring the need for further research.
At CD BioGlyco, we provide comprehensive sterile erythromycin gluceptate analysis service, offering excellent pharmaceutical analysis solutions. With well-established experimental protocols, our professional team ensures accurate and reliable results for your project. Please feel free to contact us for more details and ask for a custom analysis solution.
Reference